Revvity
RVTY · NYSE · USD · Healthcare
1What is happening
Revvity has fallen 10% since its 6-week high on 03/11/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayfrom the 6-week high-9.7%
Other view · 15 analystsHorizon: 12 months6 Buy · 11 Hold · 1 Sell2Our assessment
Dip in progress36How it continues – phase and signs – you see with a free account.
3Your next step
Marking places no order – it only helps you keep track.
More details · reasons, figures, alerts
How deep is the dip?
- from the 6-week high-9.7%
Highest daily price: $171.74 on 03/11/2026 · reference of the assessment · also the highest of the last 3 months
- from the 52-week high-9.7%
Highest price in 52 weeks: $171.74 (Yahoo)
Why is it down?
quarterly numbers- ·From its 6-week high of $171.74 on 03/11/2026 the price fell 9.7% to $155.11.
- ·The biggest single-day drop was 5.4% on 05/11/2026.
- ·That was right after the quarterly numbers. Results were 6% above expectations, so the market reacted to the outlook or details, not the headline number.
- ·No clear news driver in the last 10 days.
- ·The whole market is down 5.6% from its 60-day high, so part of this is not about the company.
- ·Other Diagnostics & Research stocks we track are down only 5.5% on average, so this is mostly about the company. See all 77 in this sector →
Drops after numbers usually take a few weeks to settle. The score already accounts for the miss.
What analysts expect
15 analysts disagree. They look about 12 months ahead – DipCatcher only 14 trading days.
- Buy
- 633 %
- Hold
- 1161 %
- Sell
- 16 %
Average price target$171.07
$122.00 to $200.00 · today $155.11
$122.00Ø $171.07$200.00
What is a price target?
The price an analyst expects in about 12 months. Estimates are often far apart and change frequently.
Third-party opinion, not an assessment by DipCatcher. Source: public analyst estimates, as of 08/11/2026. Not financial advice.
Dates
- 22JanEx-dividendBuying from this day no longer gets the next dividend. The price usually drops by about the dividend.
- 1FebQuarterly resultsRevvity reports results. Prices often move more around this date.
- 12FebDividend paymentThe dividend is paid on this day.
The company in figures
- Market value
- 17.3 bn $
- All shares together at the current price.
- P/E
- 68.9
- Price divided by earnings per share, last 12 months.
- Dividend yield
- 0.18 %
- Yearly dividend relative to the price.
- 52-week range
- $81.22 – $171.74
- Lowest and highest price of the last year.
Catalysts
37 h ago- News, last 10 days
- no recent news
- Next earnings
- 01/02/2027 · in 87 days
- Last report
- 03/11/2026 +5.7% vs estimate
Key figures
- Market value
- 17.3 bn $Large cap
- P/E
- 68.9
- Dividend yield
- 0.18 %
- Volume today
- 0.9 × Øabout usual
- Beta
- 1.09swings about like the market
- 52-week range
- $81.22 – $171.74price at 82 % of the range
About Revvity
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
- Headquarters:
- Waltham, United States
- 52-week range:
- $81.22 – $171.74
- Website:
- revvity.com
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
See which stocks they are
The engine is watching these dips right now. A free account shows the names and opens 3 full analyses a day.
- 3 full analyses a dayWith entry, target, stop and the reasons behind them.
- WatchlistFollow the stocks you care about.
Free, no payment details.
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
Not investment advice. Investing carries risk up to total loss.